AzTrials
AzTrials

HIV Infection PrimaryPhase 2NCT05780073

Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment

A Phase 2 study testing Dasatinib 70 mg in people with HIV Infection Primary, run by Fundació Institut Germans Trias i Pujol at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to evaluate the safety, tolerability and Impact of low dose Dasatinib in People with Human Immunodeficiency Virus (PWH) on suppressive Combined Antiretroviral Therapy (cART),. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
HIV Infection Primary
What is being tested?
Dasatinib 70 mg
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
1 siteSpain
Study dates
16 Oct 2023to 1 Apr 2025
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 1. Males and females aged at least 18 years on the day of screening.
  • 2. Confirmed HIV-1 infection.
  • 3. Receiving suppressive cART for at least 3 years (defined as maintained plasma viral load <50 copies/mL, allowing for isolated blips [<200 cop/ml, non-consecutive, representing <20% total determinations]).
  • 4. Being on the same ART regimen within at least 4 weeks prior to baseline visit.
  • 5. Willing and able to be adherent to their ART regimen for the duration of the study.
  • 6. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
Show all 11Show fewer
  • 7. In the opinion of the Principal Investigator, the candidate has understood the information provided and can give written Informed Consent.
  • 8. If heterosexually active female of childbearing potential, using an effective method of contraception (hormonal contraception, intra-uterine device (IUD), or anatomical sterility in self or partner) from 14 days prior to the first Investigational Medicinal Product (IMP) administration and commit to use it until 3 months after the last IMP administration. All female candidates of childbearing potential who are not heterosexually active at screening, must agree to utilize an effective method of contraception if they become heterosexually active during the study.
  • 9. If heterosexually active male, regardless of reproductive potential, sterilized or agree on the use of an effective method of contraception by his female partner (hormonal contraception, intra-uterine device (IUD), or anatomical sterility) from the day of the first IMP administration until 3 months after the last IMP administration. All male candidates who are not heterosexually active at screening, must agree to utilize an effective method of contraception if they become heterosexually active during the study.
  • 10. If female, willing to undergo urine pregnancy tests at the designated time points.
  • 11. Willing to accept blood draws at time points specified in the Schedule of Events

Who cannot join

  • 1. If female, pregnant or planning a pregnancy during the entire study or lactating.
  • 2. Current treatment with ART regimen that includes ritonavir, cobicistat or with any other drug with known relevant drug-drug interactions with dasatinib.
  • 3. Has received any immunotherapy with intent to cure or prevent HIV, including monoclonal antibodies, therapeutic or preventive vaccines within 6 months prior to baseline visit.
  • 4. Prior history of exposure to dasatinib or any other Tyrosine Kinase Inhibitor (TKI).
  • 5. Prior history of pleural effusion.
  • 6. Prior history or clinical manifestations of any physical or psychiatric disorder that could impair the subject's ability to complete the study.
Show all 30Show fewer
  • 7. Any active AIDS-defining disease or progression of HIV-related disease, except cutaneous Kaposi's sarcoma not requiring systemic therapy.
  • 8. Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical, anal, or penile intraepithelial neoplasia.
  • 9. Systemic treatment for cancer within 1 year of study entry.
  • 10. Known hypersensitivity to any component of the IMP formulation, or severe or multiple allergies to drugs or pharmaceutical agents.
  • 11. Potential participant received or plans to receive:
  • Licensed live attenuated vaccines within 28 days before or after inflammation and immune biomarkers visit (weeks 0, 2, 24 and 48).
  • other vaccines (eg, tetanus, hepatitis A, hepatitis B, rabies, pneumococcal, recombinant Herpes Zoster, Influenza, Coronavirus Disease -19 [COVID-19] vaccines) within 14 days before or after inflammation and immune biomarkers visits (weeks 0, 2, 24 and 48).
  • 12. Receipt of blood products within 3 months of study entry.
  • 13. Current or recent use (within last 3 months) of interferon or systemic corticosteroids or other immunosuppressive agents (use on inhaled steroids for asthma or topic steroids for localized skin conditions are permitted).
  • 14. Any other current or prior therapy which, in the opinion of the investigator, would make the individual unsuitable for the study or influence the results of the study.
  • 15. Any laboratory abnormalities including:
  • Hematology:
  • Hemoglobin <10.0 g/dl,
  • Absolute neutrophil count ≤3,000 /mm3,
  • Platelets ≤100,000/mm3,
  • Biochemistry:
  • Estimated glomerular filtration rate (eGFR) <60 ml/min,
  • Aspartate Transferase (AST) > 2.5 x upper limit of normal (ULN),
  • Alanine Transaminase (ALT) > 2.5 x ULN,
  • Microbiology:
  • Positive for hepatitis B surface antigen,
  • Positive for hepatitis C antibody, unless confirmed clearance of hepatitis C virus (HCV) infection (spontaneous or following treatment)
  • Positive serology indicating active syphilis requiring treatment
  • 16. Has a corrected QT interval (QTc interval) ≥470 msec (males) or ≥480 msec (females) upon confirmation on recheck at screening, has a history of risk factors for Torsades de Pointes (eg, heart failure/cardiomyopathy or family history of long QT syndrome), or is taking concomitant medications that prolong the QT/QTc interval.

Trial locations and contacts

1 site in 1 country.

Spain1 site

  • Hospital Universitari Germans Trias i Pujol

    Badalona, Barcelona, 08916

Other trials in Spain

About this study

The goal of this clinical trial is to evaluate the safety, tolerability and Impact of low dose Dasatinib in People with Human Immunodeficiency Virus (PWH) on suppressive Combined Antiretroviral Therapy (cART),.

The main question it aims to answer are:

Read more
  • How safe and tolerable is Dasatinib administered at low dose
  • To evaluate the on-target/biological effect of Dasatinib in "in vitro" T-cells activation and its durability after completion of the treatment
  • To evaluate the effect of Dasatinib on inflammation and immune activation, on the HIV-1 reservoir, and on cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) cell counts.
  • To characterize Dasatinib concentrations in plasma and its relationships with the observed effects.

Participants will be treated with Dasatinib or matched Placebo once a day for 24 weeks. Suppressive cART will remain unchanged during the entire study. Participants will be followed until week 48, in a total of eleven visits.

Read the detailed description

This is a Phase II, single-center, randomized, double-blind, placebo-controlled clinical trial in People with Human Immunodeficiency Virus (PWH) on suppressive Combined Antiretroviral Therapy (cART).

The aim is to assess safety, tolerability and Impact of low dose Dasatinib, during 24 weeks, on Viral Persistence and Inflammation in this population.

Participants will be randomized (2:1) to receive oral Dasatinib 70 mg once daily or matched placebo for 24 weeks. At week 24, Dasatinib will be discontinued and participants will be followed until week 48, in a total of eleven visits. For all participants cART will remain unchanged during the entire study.

The hypotheses of the study is that:

  • Daily administration of a low dose of dasatinib (70 mg once daily) to PWH for 24 weeks will be safe and well tolerated.
  • Dasatinib will interfere with HIV-1 persistence mechanisms contributing to chronic immune activation and inflammation status in both concordant and immune-discordant virologically suppressed PWH.
  • Dasatinib antiproliferative effect could have a significant impact on the HIV-1 reservoir size.

The primary objective of the study is to evaluate the safety and tolerability of Dasatinib in this setting. Furthermore to evaluate the on-target/biological effect on the reduction of SAM Sterile Alpha-Motif (SAM) and histidine-aspartate (HD) Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase 1 (SAMHD1) phosphorylation upon in-vitro T-cell activation, and its durability after completion of Dasatinib treatment.

Secondary objectives are to evaluate the effect of the described intervention in the on-target/biological effects attributed to dasatinib, as well as on the Inflammation and immune activation, the HIV-1 reservoir, and CD4 and CD8 cell counts. Also to characterize dasatinib concentrations in plasma and its relationships with the observed effects, and to identify predictors of maintenance of dasatinib effects in HIV reservoir and inflammatory biomarkers after dasatinib interruption.

Being tested
Dasatinib 70 mg, Placebo
Keywords
SAMHD1 phosphorylation, T-cell activation, Dasatinib, Suppressive combined Anti Retroviral Treatment

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Dasatinib 70 mgDrug

    Also called Experimental

    Commercially available tablets containing 50 and 20 mg of dasatinib will be used. The tablets will be re-capsulated to keep the study blind

  • PlaceboOther

    Also called Control

    Maltodextrin capsules with identical size and appearance (shape, size, colour and flavour) as the dasatinib-containing capsules.

Study groups in NCT05780073
Study groupRoleWhat they receive
DasatinibExperimentalDasatinib 70 mg/daily, orally administered, for 24 weeks
Receives: Drug: Dasatinib 70 mg
PlaceboPlacebo comparatorInvestigational Medicinal Product-like appearance capsule containing an inert substance,orally administered, once daily, for 24 weeks
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Grade 3 or 4 treatment-related adverse events or laboratory abnormalities during the study (based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grading scale).

    Proportion of participants (People with HIV on suppressive Combined Antiretroviral Therapy) that develop Grade 3 or 4 treatment-related adverse events or laboratory abnormalities during the study, based on the CTCAE v5.0 grading scale.

    Measured: From baseline (0) to week 48

  2. Changes in SAMHD1 (SAM And HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase 1) phosphorylation in CD4+ T cells upon in-vitro T cell activation.

    Proportion of SAM (Sterile alpha-motif ) and HD (histidine-aspartate) Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase 1 (SAMHD1) phosphorylation in CD4+ T cells upon in-vitro T cell activation.

    Measured: From Baseline (0) to week 24

  3. Changes in SAMHD1 (SAM And HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase 1) phosphorylation in CD4+ T cells upon in-vitro T cell activation.

    Proportion of SAM (Sterile alpha-motif ) and HD (histidine-aspartate) Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase 1 (SAMHD1) phosphorylation in CD4+ T cells upon in-vitro T cell activation.

    Measured: From Baseline (0) to week 48

Secondary outcomes (16)

  1. Proviral reactivation capacity upon in-vitro T-cell activation: Proportion of intracellular HIV-1 core antigen in CD4+ T cells

    Antiviral effect of Dasatinib and its durability: Proportion of intracellular HIV-1 core antigen in CD4+ T cells after in-vitro T-cell activation

    Measured: At weeks 0 (baseline) , 2, 24 and 48 weeks

  2. Proviral reactivation capacity upon in-vitro T-cell activation: Frequency of HIV-1 p24 production

    Antiviral effect of Dasatinib and its durability: Frequency of HIV-1 p24 production at a single-cell level, measured by viral protein spot (VIP-SPOT).

    Measured: At weeks 0 (baseline), 2, 24 and 48 weeks

  3. Resistance to HIV infection: Frequency of CD4+ T cells infection by NL4-3_wild type strain

    Antiviral effect of Dasatinib and its durability: Frequency of CD4+ T cells infection by NL4-3_wild type strain of HIV in vitro.

    Measured: At weeks 0 (baseline), 2, 24 and 48 weeks

  4. Plasma levels of homeostatic cytokines (interleukin-IL) IL-2, IL-7, IL-15, IL-21

    Antiviral effect of Dasatinib and its durability: Homeostatic proliferation

    Measured: At weeks 0 (baseline), 2, 24 and 48 weeks

  5. Antiviral effect of Dasatinib and its durability (Immunomodulatory effects) (Presence of cytotoxic activity in natural killer (NK) and CD8+ T cells).

    Direct cytotoxicity measured in natural killer (NK)- specific K562 cells and HIV-infected TZM cells as targets (DCC), and antibody-mediated cellular cytotoxicity (ADCC) assay using rituximab-coated Raji cells as target

    Measured: At weeks 0 (baseline) , 24 and 48 weeks

  6. Functionality of NK and CD4/CD8 T cells and its durability (Immunomodulatory effects of Dasatinib)

    Percentage of AIM+ CD4 and CD8 T cells measured by AIM (activation induced marker) multiparametric flow cytometry and percentage of polyfunctional CD4 and CD8 T cells measured by ICS (intracellular cytokine staining) assay after HIV and CMV peptide stimulation.

    Measured: At weeks 0 (baseline), 24 and 48 weeks

  7. Impact of Dasatinib and its durability on Inflammation and immune activation: plasma levels of proinflammatory biomarkers

    Plasma levels of proinflammatory biomarkers: Polymerase Chain Reaction (PCR), d-dimer, IL-6, IL-32, IL-8, (Tumor Necrosis Factor alpha) TNFa, interferon-gamma (IFNg), and sCD14.

    Measured: At weeks 0 (baseline), 2, 24 and 48 weeks

  8. Impact of Dasatinib and its durability on Inflammation and immune activation: plasma levels of anti-inflammatory biomarkers

    Plasma levels of anti-inflammatory biomarkers: IL-10, transforming growth factor beta (TGFb)

    Measured: At weeks 0 (baseline), 2, 24 and 48 weeks

  9. Impact of Dasatinib and its durability on Inflammation and immune activation: T cell frequencies with activation, exhaustion and senescence markers

    Measured by multiparametric flow cytometry assays.

    • Activation markers: chemokine receptor 7 (CCR7), cluster of differentiation 45RA (CD45RA), Human Leukocyte Antigen-DR (HLA-DR), cluster of differentiation 38 (CD38), cluster of differentiation 25 (CD25) and cluster of differentiation 69 (CD69)
    • Exhaustion markers: PD-1/LAG-3 (Programmed cell Death 1 / Lymphocyte Activation Gene 3) and TIGIT
    • Senescence markers: cluster of differentiation 28 (CD28) and cluster of differentiation 57 (CD57)

    Measured: At weeks 0(baseline) , 24 and 48 weeks

  10. Impact of Dasatinib and its durability on HIV-1 reservoir: proviral HIV-1 DNA quantification

    Total and intact (IPDA) proviral HIV-1 DNA in purified CD4 T cells

    Measured: At weeks 0 (baseline), 24 and 48 weeks

  11. Impact of Dasatinib and its durability on HIV-1 reservoir: viral load quantification

    Ultrasensitive plasma viral load quantification (usVL)

    Measured: At weeks 0(baseline) , 24 and 48 weeks

  12. Impact of Dasatinib and its durability on HIV-1 reservoir: Cell-associated HIV-RNA quantification

    Quantification of Cell-associated HIV-RNA (caHIV-RNA) in CD4+ T cells

    Measured: At weeks 0 (baseline), 2, 24 and 48 weeks

  13. Impact of Dasatinib and its durability on CD4+ T cell populations: number of CD4 T cells

    Peripheral CD4 T cell counts

    Measured: At weeks 0 (baseline), 2, 12, 24, 28, 36 and 48 weeks

  14. Impact of Dasatinib and its durability on CD4+ T cell populations: percentage of CD4 T cells

    Peripheral CD4 T cell percentage

    Measured: At weeks 0 (baseline), 2, 12, 24, 28, 36 and 48 weeks

  15. Impact of Dasatinib and its durability on CD4+ T cell populations: CD4/CD8 T cells ratio

    Peripheral T cell CD4/CD8 ratio

    Measured: At weeks 0 (baseline), 2, 12, 24, 28, 36 and 48 weeks

  16. Pharmacokinetics of Dasatinib (plasma concentrations)

    Concentrations in plasma of Dasatinib.

    Measured: At weeks 0 (baseline), 2, 12 and 24 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Mar 2023
  2. Study start16 Oct 2023
  3. Primary completion1 Apr 2025
  4. Study completion1 Apr 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05780073
Sponsor's protocol ID
BCN04-Dasa
Status last verified
Sep 2025
First submitted
27 Feb 2023
Last updated
22 Sep 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Dasatinib 70 mg in people with HIV Infection Primary, run by Fundació Institut Germans Trias i Pujol at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Grade 3 or 4 treatment-related adverse events or laboratory abnormalities during the study (based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grading scale). (time frame: From baseline (0) to week 48). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05780073.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in